Biotech | November 15, 2025
Merck to acquire Cidara Therapeutics for $9.2 billion
Diversifying its portfolio to include late-phase antiviral agent
Diversifying its portfolio to include late-phase antiviral agent
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Subscribe To Our Newsletter & Stay Updated
